Bio-Techne Corporation (TECH) M&A Call June 25, 2026 8:00 AM EDT
Company Participants
Florian Schraeder - Head of Investor Relations
Kai Beckmann - CEO & Chair of Management Board
Jean Wirth - Member of the Executive Board & CEO Life Science
Helene von Roeder - CFO & Member of Executive Board
Conference Call Participants
Sachin Jain - BofA Securities, Research Division
Peter Verdult - BNP Paribas, Research Division
Matthew Weston - UBS Investment Bank, Research Division
Richard Vosser - JPMorgan Chase & Co, Research Division
James Quigley - Goldman Sachs Group, Inc., Research Division
Charles Pitman - Barclays Bank PLC, Research Division
Rajesh Kumar
Oliver Metzger - ODDO BHF Corporate & Markets, Research Division
Falko Friedrichs - Deutsche Bank AG, Research Division
Presentation
Florian Schraeder
Head of Investor Relations
Thank you very much, Amber, and a warm welcome to everyone joining us for this update call on our announcement today to acquire Bio-Techne. My name is Florian Schraeder. I'm the Head of Investor Relations at Merck. I am delighted to be joined by Kai Beckmann, Group CEO; Helene von Roeder, Group CFO; and Jean-Charles Wirth, CEO, Life Science.
Before we start, let me emphasize that the closing of the transaction is subject to customary closing conditions, including required regulatory approvals and approval by Bio-Techne shareholders.
In the first few minutes of this update call, we would like to guide you through some key slides we published late this morning. And after that, we would be more than happy to take your questions. With that, I believe we are ready to begin. Over to you, Kai, to kick us off.
Kai Beckmann
CEO & Chair of Management Board
Thank you, Florian, and good afternoon, everybody, and thank you all for joining us today. We have exciting news today, and we are delighted to share an important milestone for our company. As announced this morning, we have signed a definitive
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。